Myovant Sciences rejects USD 2.5 billion takeover offer from Sumitovant, Sumitomo Pharma
Advertisement
US: Myovant Sciences Ltd said on Sunday it rejected a $2.5 billion takeover offer from Sumitovant Biopharma and its parent group Sumitomo Pharma Co Ltd as the bid "significantly undervalues" the U.S. drugmaker.
Sumitovant, which currently holds approximately 52% of the outstanding shares in Myovant Sciences, and Sumitomo Pharma had submitted a proposal to acquire the remaining shares in the drugmaker for $22.75 per share in cash, according to a statement.
The special committee has carefully reviewed the proposal and determined that it significantly undervalues the company and is not in the best interests of the company or its minority shareholders, Myovant Sciences said, adding it remains open to considering any improved proposal that reflects the "full and fair value" of the firm.
The proposed acquisition consideration represents an equity value of $2.4 billion and an enterprise value of $2.5 billion, Sumitovant Biopharma said in a separate statement.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.